Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- FDA Accepts Takeda’s Resubmission for Eosinophilic Esophagitis Drug
September 22, 2023
- Lecanemab to Serve as Gamechanger in Science, Treatments Set to Start by Year-End: Biogen Japan Chief
September 21, 2023
- Asahi Kasei, NCC Ink CAR-T Research Deal, Eye Launch for ATLL in 2027
September 21, 2023
- Shionogi’s Xocova Effective in High-Risk COVID Patients
September 20, 2023
- Hisamitsu Kicks Off Japan PII for Microneedle-Based Topical Sedation Drug
September 20, 2023
- Otsuka/Astex’s Oral AML Drug Nabs European OK
September 20, 2023
- European Panel Backs Enhertu Label Expansion, Quizartinib: Daiichi Sankyo
September 20, 2023
- Xtandi Accepted for Review for mHSPC in China: Astellas
September 20, 2023
- Iveric Bio’s AMD Med Nets Positive PIII Topline Data in Geographic Atrophy: Astellas
September 20, 2023
- 2 Big Wholesalers Ink Capital Tie-Up with Telehealth Player MICIN
September 19, 2023
- JT Files Tapinarof Cream for Eczema, Psoriasis in Japan
September 19, 2023
- Ex-Takeda Japan Chief Becomes Advisor for Regenerative Medicine Player
September 15, 2023
- Astellas to Set Up New Aseptic Drug Plant in Ireland
September 15, 2023
- AbbVie Files Skyrizi for Ulcerative Colitis in Japan
September 15, 2023
- Oral Flu Drug Prescriptions 10 Times More than Pre-COVID: August Survey
September 15, 2023
- FDA Accepts for Review Takeda’s Entyvio SC Form for Crohn’s
September 15, 2023
- Gilead’s Multi-Drug Resistant HIV Med Now Available in Japan
September 14, 2023
- Xtandi Accepted for EMA Review for Earlier Type of Prostate Cancer
September 14, 2023
- Pfizer Japan Files 20-Valent Pneumococcal Jab for Older Adults, High-Risk People
September 14, 2023
- Daiichi Sankyo Aims to Develop ADC DS-7300 beyond Current 4 Cancers: Exec
September 13, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…